SK Capital Partners signs deal to buy Apotex Pharmaceutical Holdings
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.99/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19.95 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 28/09/2022 (1198 days ago), so information in it may no longer be current.
TORONTO – Apotex Pharmaceutical Holdings Inc. has signed a deal to be acquired by U.S. private equity investment firm SK Capital Partners.
Financial terms of the agreement for the Canadian drug company were not immediately available.
Aaron Davenport, managing director at SK Capital, says Apotex is a dynamic, entrepreneurial company with a strong track record of success, underpinned by its diversified product portfolio, robust pipeline of new launches and iconic brand.
Apotex employs nearly 8,000 people around the world in manufacturing, research and development and commercial operations.
It operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico and India.
The deal is subject to customary regulatory conditions.
This report by The Canadian Press was first published Sept. 28, 2022.